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Abstract
Hyperuricemia, hyperlipidemia and inflammation are associated with diabetic nephropathy. The NLRP3 inflammasome-
mediated inflammation is recently recognized in the development of kidney injury. Urate and lipid are considered as danger
signals in the NLRP3 inflammasome activation. Although dietary flavonoid quercetin and allopurinol alleviate hyperuricemia,
dyslipidmia and inflammation, their nephroprotective effects are currently unknown. In this study, we used streptozotocin
(STZ)-induced diabetic nephropathy model with hyperuricemia and dyslipidemia in rats, and found over-expression of renal
inflammasome components NLRP3, apoptosis-associated speck-like protein and Caspase-1, resulting in elevation of IL-1b
and IL-18, with subsequently deteriorated renal injury. These findings demonstrated the possible association between renal
NLRP3 inflammasome activation and lipid accumulation to superimpose causes of nephrotoxicity in STZ-treated rats. The
treatment of quercetin and allopurinol regulated renal urate transport-related proteins to reduce hyperuricemia, and lipid
metabolism-related genes to alleviate kidney lipid accumulation in STZ-treated rats. Furthermore, quercetin and allopurinol
were found to suppress renal NLRP3 inflammasome activation, at least partly, via their anti-hyperuricemic and anti-
dyslipidemic effects, resulting in the amelioration of STZ-induced the superimposed nephrotoxicity in rats. These results
may provide a basis for the prevention of diabetes-associated nephrotoxicity with urate-lowering agents such as quercetin
and allopurinol.
Citation: Wang C, Pan Y, Zhang Q-Y, Wang F-M, Kong L-D (2012) Quercetin and Allopurinol Ameliorate Kidney Injury in STZ-Treated Rats with Regulation of Renal
NLRP3 Inflammasome Activation and Lipid Accumulation. PLoS ONE 7(6): e38285. doi:10.1371/journal.pone.0038285
Editor: Samithamby Jeyaseelan, Louisiana State University, United States of America
Received July 26, 2011; Accepted May 3, 2012; Published June 11, 2012
Copyright:  2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Natural Science Foundation of China (NSFC 81025025), National Basic Research Program of China 973
Program No. 2012CB517600 (No. 2012CB517602), Jinagsu Natural Science Foundation (BK2010365) and Program for Changjiang Scholars and Innovative Research
Team in University (IRT1020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kongld@nju.edu.cn
. These authors contributed equally to this work.
Introduction
Kidney injury is the most common pathological disorder
predisposing end-stage renal disease worldwide [1–3]. Hyperuri-
cemia, hyperlipidemia and inflammation are associated with the
development and progression of diabetic kidney injury [2–6]. Uric
acid contributes to the secretion of proinflammatory cytokines
such as interleukin 1b (IL-1b) and IL-18 [7]. The elevated IL-1b
and IL-18 levels are observed in diabetic patients with nephrop-
athy [2,8–10]. The NOD-like receptors (NLRs) are a family of
intracellular sensors of danger-associated molecular patterns. NLR
protein 3 (NLRP3, also known as NALP3/Cryopyrin) interacts
with the bridging molecule apoptosis-associated speck-like protein
(ASC) to activate caspase-1, which is essential for mature IL-1b
and IL-18 production [7,11,12]. The NLRP3 inflammasome
activation promotes kidney injury process with up-regulation of
IL-1b and IL-18 [13,14] and enhances IL-1b levels in the type 2
diabetes [15]. It is noted that high uric acid level is a causative
factor of the NLRP3 inflammasome-mediated inflammation in
lung injury [7]. Dyslipidemia is involved in the retarded urate
clearance, causing the elevated serum uric acid level [16]. Free
fatty acids synergistically enhance urate to activate the NLRP3
inflammasome [17], being responsible for obesity-induced inflam-
mation and insulin resistance in fat depots of mice [18]. Therefore,
serum level of uric acid is suggested as a new player in the
development of diabetic nephropathy [5,6]. Interestingly, allopu-
rinol, an inhibitor of uric acid synthesis, reduces hemozoin-
induced NLRP3 inflammasome activation [19] and controls IL-1b
production in inflammasome-deficient mice [7]. The previous
studies from our and other laboratories show that allopurinol
reduces serum total cholesterol (TC) and triglycerides (TG) levels
and ameliorates renal histopathology in fructose-fed rats [20,21].
Allopurinol also exerts renoprotective action in the type 2 diabetic
db/db mice [22] and patients with diabetic kidney injury [23].
These observations suggest that the NLRP3 inflammasome may
be a therapeutic target for urate-lowering treatment in diabetes
with kidney injury driven by hyperuricemia and dyslipidemia.
Dietary flavonoid quercetin is used as a hypouricemic agent
[20]. Our previous study showed that quercetin attenuated
fructose-induced hyperuricemia and renal dysfunction through
the regulation of renal urate transport-related proteins such as
short isoform of glucose transporter 9 (rGLUT9), renal-specific
transporter (rRST), organic anion transporters 1 (rOAT1) and
electrogenic urate transporter (rUAT) in rats [20]. Moreover,
quercetin improves dyslipidemia and hyperinsulinemia in obese
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38285Zucker rats [24], fructose-fed rats [20] and atherogenic diet-fed
mice with hepatic lipid accumulation [25], as well as reduces
inflammation in visceral adipose tissue [25], primary human
adipocytes [26] and the kidney of fructose-fed rats [20]. It also
prevents diabetic kidney injury in rats [27]. However, the
mechanisms by which quercetin and allopurinol protect against
diabetic kidney injury are incompletely understood.
Streptozotocin (STZ) is known to develop diabetic kidney injury
with hyperuricemia, hyperlipidemia and inflammation [6,28]. The
purpose of the present study was then to determine if the NLRP3
inflammasome was activated with the exacerbated production of
IL-1b and IL-18 in the kidney of STZ-induced diabetic rats
associated with high urate level and lipid metabolism abnormality,
and conversely, if quercetin and allopurinol inhibited renal
NLRP3 inflammasome activation involved in their actions on
hyperuricemia and lipid metabolism disorder in this model.
Materials and Methods
Animals
Male Sprague-Dawley rats (5-week old and 200–220 g weight),
were purchased from Laboratory Animal Center (Zhejiang
Province, P. R. China). They were individually housed and
maintained at a temperature of ,22uC with a relative humidity of
,55%, acclimatized for at least a week before further operation.
Water and food were provided ad lib and light was set to a 12 h
light/dark cycle (lights on at 8 a.m.). All protocols including
diabetes induction and sacrifice operation had been approved by
the Institutional Animal Care and Use Committee at the Nanjing
University and the China Council on Animal Care at Nanjing
University.
Experimental Design
Rats were fasted overnight and then given a single intraperi-
toneal injection of freshly 55 mg/kg STZ (St Louis, MO, USA) in
0.1 M citrate buffer (pH 4.4) in a dark environment, while normal
control animals were received only citrate buffer. The rats, whose
fasting blood glucose levels in tail vein were above 250 mg/dL
72 h after STZ injection using glucose assay kit purchased from
Jiancheng Biotech (Nanjing, P. R. China), were considered as
diabetes. These successful model rats of diabetes were further
divided into 5 groups (n=8): diabetic control treated with water,
diabetic rats treated with quercetin (25, 50 and 100 mg/kg), and
allopurinol (10 mg/kg, a positive drug) (St Louis, MO, USA),
respectively. The doses chosen were based on our and other
previous preclinical experiments [29–32]. The treatment was
started on 4th day after STZ injection by gavage once daily at
9:00 a.m.–10:00 a.m. for the subsequent 7 weeks.
General Condition, Uric Acid and Kidney Function
Body weight and blood glucose levels of rats were recorded
before and after STZ induction at each week, including drug
treatment period. Blood samples were collected from rat tail vein,
left to clot in pre-iced tubes and centrifuged at 3,0006g,4 uC for
5 min to get serum. Urine samples were collected with metabolic
Table 1. The primers used for Real-Time PCR.
Gene Forward primer 5’R 3’










































Normal Control 411.3 6 6.5 0.63 6 0.04 37.03 6 2.15 3.39 6 0.48 17.30 6 1.41
STZ Control 177.1 6 2.9
+++ 1.57 6 0.16
+++ 297.94 6 5.17
+++ 454.50 6 31.45
+++ 42.21 6 1.91
+++
STZ + quercetin 100 223.4 6 3.5
*** 0.97 6 0.08
** 222.32 6 9.52
*** 322.49 6 33.97
* 26.58 6 3.95
**
STZ + quercetin 50 221.8 6 2.3
*** 1.29 6 0.16 278.54 6 8.30 346.94 6 11.74
* 30.27 6 3.25
*
STZ + quercetin 25 204.6 6 5.0
*** 1.50 6 0.08 282.34 6 3.55 397.15 6 34.78 38.48 6 0.86
STZ + allopurinol 10 221.3 6 4.3
*** 1.05 6 0.13
* 218.33 6 9.98
*** 316.75 6 30.52
* 24.67 6 2.24
***
The data are expressed as the means 6 SEM (n=8).
+++P,0.001 versus normal control;
*P,0.05,
**P,0.01,
***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.t002
Quercetin Diminishes STZ-Diabetic Kidney Injury
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30006g for 5 min to remove the impurity. The samples were
stored at 220uC for the assays. Serum and urine glucose levels
were detected as above. Urinary creatinine (Cr), blood urea
nitrogen (BUN) and albumin levels were determined by specific
commercial kits purchased from Jiancheng Biotech (Nanjing, P. R.
China). Uric acid (UA) levels in serum and urine were determined
as previously reported [20]. Clearance rates of 24-h urine uric acid
(Ucr), creatinine (Ccr) and BUN were calculated by the formula:
Ucr/Ccr/BUN = urine UA/Cr/BUN concentration (mmol/L)6
urine volume (L) in 24-h/serum UA/Cr/BUN (mmol/L)/1440.
The Kidney-to-Body Weight Ratio and the Measurements
of Serum and Tissue Samples
At the end of drug treatment, all animals were deprived of food
but not water until the following morning. Rats were sacrificed by
decapitation 1 h after the last administration between 9 a.m. and
10 a.m. Blood samples were collected as above. The kidney was
quickly dissected and weighted (for calculation of the quot of
kidney, the ratio of wet kidney weight/body weight). The left
kidney cortex tissues were immediately frozen in liquid nitrogen.
The separated serum and kidney tissues were stored at 280uC
for the measurements of TC, TG and non-esterified fatty acid
(NEFA) levels by respective kits obtained from Jiancheng Biotech
(Nanjing, P. R. China) and of IL-1b and IL-18 levels by ELISA
kits (R & D).
Histopathology
Kidney tissue from rats was immediately fixed for 1 day at room
temperature in formalin and preserved in 70% ethanol. Renal
biopsies were dehydrated with a graded series of alcohol and
embedded in paraffin. Specimens were cut in 7-mm-thick section
on a rotary microtome and mounted on APES-coated glass slide.
Each section was deparaffinized in xylene, rehydrated in
decreasing concentrations of alcohol in water and stained with
hematoxylin-eosin (HE) reagent and periodic-acid schiff with
diastase (PAS-D) reagent (Sigma Chemicals Co, St. Louis, MO),
respectively. The slide was mounted with neutral balsam.
Other rat kidney tissues were snap-frozen immediately at
270uC. 6-mm-thick cryostat section was prepared on APES-coated
glass slide. Each section was washed by distilled water and then
stained with oil-red O reagent (Sigma Chemicals Co, St. Louis,
Figure 1. Quercetin and allopurinol restore streptozotocin (STZ)-induced hyperuricemia and kidney dysfunction in rats. Biochemical
analyses showed uric acid (A-C), creatinine (D-F) and urea nitrogen (G-I) levels in serum and urine, as well as their clearance rates at 7 weeks after STZ
injection in different groups of rats as indicated. The data are expressed as the means 6 SEM (n=8).
+++P,0.001 versus normal control; *P,0.05,
**P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38285Figure 2. Quercetin and allopurinol regulate renal urate transport-related proteins in streptozotocin (STZ)-treated rats.
Representative Western blot results (A) and graphic presentation showed renal protein expression of rOAT1 (B), rOAT3 (C), rUAT (D), rGLUT9 (E)
and rRST (F) at 7 weeks after STZ injection in different groups of rats as indicated. The relative protein levels of rOAT1, rOAT3, rUAT and rGLUT9 were
determined after normalization with rGAPDH. The relative BBMV rRST protein levels were normalized to rNa
+-K
+-ATPase. The data are expressed as
the means 6 SEM (n=3–4).
++P,0.01,
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g002
Figure 3. Quercetin and allopurinol regulate renal urate transport-related proteins mRNA in streptozotocin (STZ)-treated rats.
Graphic presentation of renal mRNA levels by real-time PCR analysis of rOAT1 (A), rOAT3 (B), rUAT (C), rGLUT9 (D) and rRST (E) in different groups of
rats as indicated. The relative mRNA levels were determined after normalization with rGAPDH. The data are expressed as the means6SEM (n=3–4).
++P,0.01,
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g003
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sections were re-stained by hematoxylin.
Real-Time Quantitative PCR Analysis
Total RNA isolated from individual rat kidney with Trizol
reagent (Invitrogen) following the manufacturer’s protocol, was to
evaluate mRNA expressions of urate transport-related genes
(rOAT1, OAT3, rUAT, rRST and rGLUT9), lipid metabolism-
related genes [peroxisome proliferator-activated receptor-a
(PPAR-a), carnitine palmitoyl transferase 1 (CPT1), organic
cation/canitine transporter 2 (OCTN2), acetyl-CoA carboxylase
2 (ACC2)], NLRP3 inflammasome (rNLRP3, rASC, rCaspase-1)
and glyceraldehyde 3-phosphate dehydrogenase (rGAPDH). The
reverse transcribed cDNA using SuperScript First-Strand Synthe-
sis kit (RT-PCR; Invitrogen). The primers used for Real-Time
PCR were summarized in Table 1. All primer sequences were
checked in GenBank to avoid inadvertent sequence homologies.
They were designed and synthesized by Biogenes Biotechnology
(Nanjing, R. P. China). Reactions were performed using SYBR-
Green PCR master mix (Applied Biosystems) in a BioRad iCycler
iQ Detection System. As an internal control, rGAPDH levels were
quantified in parallel with target genes. Normalization and fold
change for each of the genes were calculated using the 2-Delta
Delta C (T) method [33].
Western Blot
About 100 mg of frozen rat kidney tissues were homogenized in
1 mL RIPA buffer, and then centrifuged at 10,0006g for 20 min.
Figure 4. Quercetin and allopurinol reduce lipid levels in streptozotocin (STZ)-treated rats. Biochemical analyses showed serum and
kidney cortex levels of TC (A), TG (B) and NEFA (C) at 7 weeks after STZ injection in different groups of rats as indicated. The data are expressed as the
means 6 SEM (n=8).
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g004
Figure 5. Quercetin and allopurinol reduce renal lipid accumulation in streptozotocin (STZ)-treated rats. Representative micrographs
demonstrated kidney histology in different groups of rats. Kidney sections were stained with oil-red O. Normal control (A), STZ alone (B), STZ plus
100 mg/kg quercetin (C), STZ plus 50 mg/kg quercetin (D), STZ plus 25 mg/kg quercetin (E) and STZ plus 10 mg/kg allopurinol (F). Bar=50 mmi n
Fig. 5A.
doi:10.1371/journal.pone.0038285.g005
Quercetin Diminishes STZ-Diabetic Kidney Injury
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Bradford method. The total proteins were incubated in boiling
water for 5 min. Equal amount of total protein was separated on
6–12% SDS-PAGE and electrophoretically transferred to poly-
vinylidene difluoride (PVDF) membrane (Millipore, Shanghai, P.
R. China) pre-activated by methanol in the transferring buffer.
Membranes were blocked with 5% skimmed milk for 2 h, and
incubated overnight with specific primary antibodies at 4uC.
Immunoreactive bands were detected using HRP-conjugated goat
anti-rabbit or goat anti-rat IgG as the secondary antibody (1:5,000)
(Jingmei Biotech, Shanghai, P. R. China). Immunoreactive bands
were visualized using phototope-horseradish peroxidase Western
blot detection system (Cell Signaling Technologies, Beverly, MA)
and quantified by densitometry using Molecular Analyst Software
(Bio-Rad Laboratories, Hercules, CA). Primary antibodies includ-
ed rabbit polyclonal antibodies against rOAT1 (1:2,000), rOAT3
(1:2,000), rUAT (1:200) and rGLUT9 (1:1000) (Sai-Chi Biotech.
Beijing, P. R. China), rCPT1 (1:3,000), rACC2 (1:2,000),
phosphorylation of rACC2 (p-rACC2, Ser219/Ser221, 1:2,000)
(Santa Cruz Biothchnology. CA), rPPAR-a (1:2,000), rASC
(1:1,000), rCaspase-1 (1:1,000) (Abcam Ltd. Hong Kong),
rNLRP3 (1:500) (Novus Biologicals, Inc. USA), rIL-1b (we
detected both mature- and pro-IL-1b, 17 and 31 kD, respectively)
(1:1000) (Abcam Ltd. Hong Kong), rIL-18 (we detected both
mature- and pro-IL-1b, 18 and 24 kD, respectively) (1:500) (Santa
Cruz Biothchnology. CA) and rat GAPDH (1:5,000) (Kangcheng
Biotech., Shanghai, P. R. China).
Renal cortical brush-border membrane vesicles were prepared
from rat kidneys as previously reported [20]. Briefly, kidney cortex
slices were homogenized for 2 min in 10 mM Hepes buffer 1
(300 mM D-mannitol, 5 mM EGTA, 12 mM MgCl2, pH 7.4).
After staying for 20 min, the homogenate was centrifuged at
2,4006g for 15 min. The supernatant was centrifuged at 30,0006g
for 30 min. The pellet was resuspended and homogenized in Hepes
buffer 2 (150 mM D-mannitol, 2.5 mM EGTA, 12 mM MgCl2,
pH 7.4) by a glass-Teflon homogenizer. The homogenate was
again centrifuged at 2,4006g for 15 min and the supernatant was
centrifuged at 30,0006g for 30 min. The final pellets were applied
for Western blot analysis as described above and primary
antibodies of rRST (1:2000), rOCTN2 (1:1000) (Sai-Chi Biotech.
Beijing, P. R. China) and rat Na
+-K
+-ATPase (1:1000) (Cell
Signaling Technology, Boston, MA) were used, respectively.
Statistical Analysis
Data were expressed as the mean 6 standard error of the mean
(SEM) deviation. Statistical analysis was performed by a one-way
Figure 6. Quercetin and allopurinol regulate renal mRNA levels of lipid metabolism-related genes in streptozotocin (STZ)-treated
rats. Graphic presentation of renal mRNA levels by real-time PCR analysis of rPPAR-a (A), rCPT1 (B), rACC2 (C) and rOCTN2 (D) at 7 weeks after STZ
injection in different groups of rats as indicated. The relative mRNA levels were determined after normalization with rGAPDH. The data are expressed
as the means 6 SEM (n=3–4).
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g006
Quercetin Diminishes STZ-Diabetic Kidney Injury
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Kuel’s test. Differences were considered significant at p,0.05. The
figures were obtained by the Statistical Analysis System (GraphPad
Prism 4, GraphPad Software, Inc. San Diego, CA).
Results
Quercetin and Allopurinol Ameliorate Basic
Characteristics of STZ-Treated Rats
As shown in Table 2, quercetin at 25, 50 and 100 mg/kg
significantly increased body weight (27.5–46.3 g higher than STZ
control group, p,0.001, 0.001 and 0.001), the highest dose
decreased kidney-to-body weight ratio (61.8% of STZ control
group, p,0.01) and blood glucose levels (74.6% of STZ control
group, p,0.001) in STZ-induced diabetic rats compared with
normal control group. STZ induced high levels of urine glucose
(137-fold higher, p,0.001) and protein (2.44-fold higher, p,0.001)
compared with normal control group (urine glucose:
3.3960.48 mg/dL; urine protein: 17.3061.41 mg/mL). 50 and
100 mg/kg quercetin also reduced urine levels of glucose (76.3 and
70.9% of STZ control group, p,0.05 and 0.05) and protein (71.7
and 63.0% of STZ control group, p,0.05 and 0.01), preventing
glucosuria and proteinuria in STZ-treated rats. 10 mg/kg
allopurinol exhibited its improvement on all these abnormalities
in this model.
Quercetin and Allopurinol Improve Renal Dysfunction
and Hyperuricemia through Regulating Expression Levels
of Renal Urate Transport-related Proteins in Stz-treated
Rats
As shown in Fig. 1A–I, STZ decreased total amount and
clearance rate of uric acid (amount: 28.6% and clearance rate:
16.1% of normal control group, p,0.001 and 0.001), creatinine
(amount: 27.2% and clearance rate: 19.2% of normal control
group, p,0.001 and 0.001) and BUN (amount: 22.8% of
normal control group, p,0.001) in 24-h urine, with the
elevation of serum uric acid (1.9-fold higher than normal
control group, p,0.001), creatinine (1.45-fold higher than
normal control group, p,0.001) and BUN (2.95-fold higher
than normal control group, p,0.001) concentrations in rats,
indicating the shutdown of kidney function. STZ-treated rats
receiving quercetin and allopurinol showed significant amelio-
ration of renal dysfunction and hyperuricemia.
Previous studies suggest the role of renal OATs, UAT, GLUT9
and RST in renal urate excretion and hyperuricemia [20,34]. We
examined the effects of quercetin and allopurinol on the
expression levels of these renal transporters. Partly consistent with
the previous reports in STZ-treated mice [35–36], the decreased
mRNA and protein levels of renal rOAT1 (mRNA: p,0.001;
protein: p,0.01), rOAT3 (mRNA and protein: p,0.01) and
rUAT (mRNA: p,0.01; protein: p,0.001) with the increased
mRNA and protein levels (p,0.01) of rGLUT9 and rRST were
observed in STZ-induced diabetic rats compared with normal
control group (Fig. 2A–F, 3A–F). Quercetin and allopurinol
restored STZ-induced expression abnormality of these renal urate
transporters at mRNA and protein levels in rats (Fig. 2A–F, 3A–
E), and 100 mg/kg quercetin reached the significant improvement
similar to allopurinol, further demonstrating their anti-hyperuri-
cemic effects.
Quercetin and Allopurinol Reduce Dyslipidemia and
Renal Lipid Accumulation through Regulating Lipid
Metabolism-related Genes in Stz-treated Rats
We next examined the effects of quercetin and allopurinol on
dyslipidemia and renal lipid accumulation in STZ-treated rats.
The 12-h fasting alters lipid metabolism-related genes and induces
Figure 7. Quercetin and allopurinol regulate renal expression of lipid metabolism-related genes protein levels in streptozotocin
(STZ)-treated rats. Representative Western blot results (A) and graphic presentation showed renal protein expression of rPPAR-a (B), rCPT1 (C),
rACC2 (D), p-rACC2 (E) and rOCTN2 (F) in different groups of rats as indicated. Relative protein levels of rPPAR-a, rCPT1 and rACC2 were determined
after normalization with rGAPDH. The relative renal BBMV rOCTN2 protein levels were normalized to rNa
+-K
+-ATPase. The data are expressed as the
means 6 SEM (n=3–4).
++P,0.01,
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g007
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detected serious lipid accumulation in the kidney of STZ-treated
rats compared with normal control group (Fig. 4–5). As shown in
Fig. 4A–C, STZ induced elevation of serum and kidney levels of
TC (serum: 1.3-fold; kidney: 2.5-fold higher than normal control
group), TG (serum and kidney: 1.9-fold higher than normal
control group) and NEFA (serum and kidney: 2.0-fold higher than
normal control group) in rats, which were restored effectively by
the treatment of 50 and 100 mg/kg quercetin (TC in serum and
kidney: p,0.001; TG in serum: p,0.01 and 0.001, in kidney:
p,0.001; NEFA in serum: p,0.01 and 0.001, in kidney: p,0.001
and 0.001). 10 mg/kg allopurinol restrained three types of lipids in
the kidney of STZ-treated rats. These results were consistent with
and supported by renal lipid deposition improvement in renal
tubular epithelial cells of STZ-treated rats receiving quercetin or
allopurinol assessed by oil red O-stain analysis (Fig. 5A–F).
PPAR-a is a key regulator of its target genes CPT1 and
OCTN2, both of which are involved in mitochondrion fatty acid
b-oxidation [35]. OCTN2 is capable of transporting L-carnitine
[36], which acts as an obligatory co-factor for fatty acid b-
oxidation by facilitating transportation of long-chain fatty acids
across mitochondrial membrane. CPT1 is demonstrated to
mediate transportation of long-chain fatty acids across mitochon-
dria outer membrane by binding them to L-carnitine [38].
Therefore, we investigated the expression levels of these renal lipid
metabolism-related genes in STZ-treated rats. Renal rPPAR-a,
rCPT1 and rOCTN2 mRNA (rPPAR-a: p,0.01; rCPT1: p,0.01;
rOCTN2: p,0.01) (Fig. 6A–B, D) and protein (rPPAR-a:
p,0.001; rCPT1: p,0.001; rOCTN2: p,0.001) (Fig. 7A–C, F)
levels were down-regulated in STZ-induced diabetic rats com-
pared with normal control group. Of note, the decreased L-
carnitine levels in serum (61% of normal control group, p,0.001)
and kidney (38.8% of normal control group, p,0.001) as well as
the increased L-carnitine levels in urine (4.8-fold higher than
normal control group, p,0.001) were detected in this model
(Fig. 8A–C). ACC catalyzes biotin-dependent carboxylation of
acetyl-CoA to produce malonyl-CoA. ACC2-generated malonyl-
CoA functions as inhibitor of CPT1 activity and the transfer of
fatty acyl group through the carnitine/palmitoyl shuttle system to
inter mitochondria for b-oxidation [39]. Accordingly, rACC2
mRNA (2.1-fold higher than normal control group, p,0.001)
(Fig. 6C) and protein (1.9-fold higher than normal control group,
p,0.001) (Fig. 7A, D) levels were substantially increased, whereas,
p-rACC2 (Ser 219/Ser 221) protein levels (22.3% of normal
control group, p,0.001) (Fig. 7A, E) was suppressed in the kidney
of STZ-treated rats. These results demonstrated disorders of these
lipid regulators in this model. Of interest, administration of 50 and
100 mg/kg quercetin and 10 mg/kg allopurinol effectively elevat-
ed rPPAR-a (mRNA: 50 mg/kg quercetin p,0.05, 100 mg/kg
quercetin p,0.01, 10 mg/kg allopurinol p,0.05; protein: 50 mg/
kg quercetin p,0.05, 100 mg/kg quercetin p,0.001, 10 mg/kg
allopurinol p,0.01) (Fig. 6A, 7A–B), correspondingly, restrained
down-expression of rCPT1 (mRNA: 100 mg/kg quercetin
p,0.05, 10 mg/kg allopurinol p,0.05; protein: 100 mg/kg
quercetin p,0.01, 10 mg/kg allopurinol p,0.01) (Fig. 6B, 7A,C)
and rOCTN2 (mRNA: 50 mg/kg quercetin p,0.05, 100 mg/kg
quercetin p,0.01, 10 mg/kg allopurinol p,0.01; protein: 50 mg/
kg quercetin p,0.05, 100 mg/kg quercetin p,0.001, 10 mg/kg
allopurinol p,0.001) (Fig. 6D, 7A, F) in the kidney of STZ-treated
rats compared with STZ control group. They also increased
kidney and serum L-carnitine levels and reduced urine L-carnitine
levels in this model (Fig. 8). In addition, quercetin and allopurinol
restored STZ-induced alteration in renal rACC2 expression
(mRNA: 50 mg/kg quercetin p,0.05, 100 mg/kg quercetin
p,0.01, 10 mg/kg allopurinol p,0.01; protein: 50 mg/kg quer-
cetin p,0.05, 100 mg/kg quercetin p,0.01, 10 mg/kg allopurinol
p,0.001) and p-rACC2 (50 mg/kg quercetin p,0.05, 100 mg/kg
quercetin p,0.001, 10 mg/kg allopurinol p,0.01) levels in rats
(Fig. 6C, 7A, D, E). These results suggested that quercetin and
Figure 8. Quercetin and allopurinol regulate renal L-carnitine
levels in streptozotocin (STZ)-treated rats. Biochemical analyses
showed L-carnitine levels in serum (A) and urine (B) and kidney (C) at 7
weeks after STZ injection in different groups of rats as indicated. The
data are expressed as the means 6 SEM (n=8).
+++P,0.001 versus
normal control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g008
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lipid metabolism in STZ-treated rats.
Quercetin and Allopurinol Ameliorate Kidney
Inflammation by Blocking the NLRP3 Inflammasome
Activation in STZ-treated Rats
High urate level and lipid disorder are associated with
inflammation [4,7,11,12]. In parallel with hyperuricemia and
lipid accumulation, STZ-treated rats showed inflammatory cell
infiltration in glomerulus and renal tubular (Fig. 9A) and the
destroyed kidney structure as mesangial expansion (Fig. 9B). These
kidney pathological changes in this model were ameliorated by the
treatment of quercetin and allopurinol (Fig. 9A–B).
To provide mechanistic insights into nephroprotective efficacy
of quercetin and allopurinol in STZ-treated rats, we investigated
their effects on renal NLRP3 inflammasome activation, because
recent studies suggest that this inflammasome is involved in kidney
injury [13,14]. Western blot analyses demonstrated that the
expression levels of renal rNLRP3 (p,0.05), rASC (p,0.001) and
rCaspase-1 (for Western blot analysis of rCaspase-1, we detected
the active subunit P20) (p,0.001) were increased in STZ-treated
rats compared with normal control group (Fig. 10A–D). PCR
analyses found the induced elevation of renal mRNA levels of
rNLRP3 (p,0.01) and rCaspase-1(p,0.05) in this model com-
pared with normal control group (Fig. 10E–G). The activated
caspase-1 contributes to the maturation of IL-1b and IL-18
[13,14]. Consistent with the increased ratio (2.1-fold higher than
normal control rats) of mature-IL-1b (17 kD)/pro-IL-1b (31 kD),
the similar maturative effect (1.5-fold higher than normal control
group) induced by Caspase-1 was also observed in the kidney of
STZ-treated rats by analyses of mature-IL-18 (18 kD)/pro-IL-18
(24 kD) (Fig. 10H–J). Accordingly, serum and kidney concentra-
tions of IL-1b (serum: 2.1-fold; kidney: 1.4-fold higher than
normal control rats) and IL-18 (serum: 1.7-fold; kidney: 1.9-fold
higher than normal control rats) were remarkably elevated in
STZ-treated rats (Fig. 9C–F). These results might provide
evidence for a role of the NLRP3 inflammasome activation in
STZ-induced renal inflammation under pathologic condition of
hyperuricemia and dyslipidemia in rats. We found that this over-
expression of renal rNLRP3, rASC and rCaspase-1 (P20) in STZ-
treated rats was restrained dramatically by the treatment of
100 mg/kg quercetin (rNLRP3: mRNA p,0.01, protein p,0.01;
rASC: protein p,0.001; rCaspase-1: mRNA p,0.05, protein
p,0.001), and 10 mg/kg allopurinol (rNLRP3: mRNA p,0.05,
protein p,0.01; rASC: protein p,0.001; rCaspase-1: protein
p,0.01) compared with STZ control group (Fig. 10A–G).
100 mg/kg quercetin and 10 mg/kg allopurinol also reduced
serum and kidney levels of IL-1b (serum: 100 mg/kg quercetin
p,0.001, 10 mg/kg allopurinol p,0.05; kidney: 100 mg/kg
quercetin p,0.001, 10 mg/kg allopurinol p,0.01) and IL-18
(serum: 100 mg/kg quercetin p,0.001, 10 mg/kg allopurinol
p,0.05; kidney: 100 mg/kg quercetin p,0.001, 10 mg/kg allo-
purinol p,0.01) (Fig. 9C–F) in this model, with the restoration of
renal mature-IL-1b/pro-IL-1b changes (100 mg/kg quercetin
p,0.01, 50 mg/kg quercetin p,0.05, 10 mg/kg allopurinol
p,0.05) but not renal mature-IL-18/pro-IL-18 (Fig. 10H–J). By
reducing urate and lipid levels, the NLRP3 inflammasome
activation may be suppressed by the treatment with quercetin
and allopurinol to protect STZ-induced kidney injury.
Figure 9. Quercetin and allopurinol attenuate inflammation in streptozotocin (STZ)-treated rats. HE stain (A) analyses showed
inflammatory cell infiltration and PAS-D stain (B) analyses showed kidney structures in different groups of rats. Normal control (a), STZ alone (b), STZ
plus 100 mg/kg quercetin (c), STZ plus 50 mg/kg quercetin (d), STZ plus 25 mg/kg quercetin (e) and STZ plus 10 mg/kg allopurinol (f); Bar=50 mmi n
Fig. 9Aa and Bar=15 mm in Fig. 9Ba. Biochemical analyses showed serum and kidney levels of IL-1b (C, E) and IL-18 (D, F) at 7 weeks after STZ
injection in different groups of rats as indicated. The data are expressed as the means 6 SEM (n=8).
+++P,0.001 versus normal control; *P,0.05,
**P,0.01, ***P,0.001 versus STZ control.
doi:10.1371/journal.pone.0038285.g009
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Uric acid is a mediator of diabetic kidney injury [5,6,40]. The
present study also observed hyperuricemia and kidney function
decline in STZ-induced diabetic rats. Partly consistent with the
previous reports in STZ-treated mice [41,42], deregulation of
renal rOAT1, rOAT3, rUAT, rGLUT9 and rRST may increase
urate reabsorption and decrease urate secretion, subsequently
resulting in renal urate under-excretion and serum urate elevation
in STZ-induced diabetic rats. Chronic treatment of quercetin and
allopurinol restored expression abnormality of these renal urate
transport-related proteins to enhance urate excretion and reduce
serum urate levels in STZ-treated rats, which were parallel with
our previous study in fructose-induced hyperuricemia and kidney
injury in rats [20]. These observations demonstrate that urate-
lowering efficacy of quercetin and allopurinol may improve renal
function and injury in STZ-treated rats.
Hyperuricemia is associated with dyslipidemia [16]. The altered
lipid metabolism is suggested to be responsible for the progression
of diabetic renal disease [3,43]. PPAR-a mediates lipid metabo-
lism and inflammation [30,44,45] and plays a role in the
development of diabetic kidney injury [46,47]. Down-regulation
of renal PPAR-a was detected in STZ-induced diabetic rats in the
present study. Additionally, PPAR-a regulates CPT1 and OCTN2
involved in mitochondrion fatty acid b-oxidation [35]. Experi-
mental studies have demonstrated that L-carnitine reduces serum
TG and TC levels and improves lipid metabolism in STZ-induced
diabetic rats [48], relieves lipid overload in obese rodents with
diabetes [49] and prevents renal injury [50]. The present study
Figure 10. Quercetin and allopurinol inhibit renal NALP3 inflammasome activation in streptozotocin (STZ)-treated rats.
Representative Western blot results (A) and graphic presentation showed renal protein expression of rNALP3 (B), rASC (C) and rCaspase-1 (D) in
different groups of rats as indicated. Relative protein levels of rNALP3, rASC and rCaspase-1 were determined after normalization with rGAPDH. For
rCaspase-1, the active subunit of P20 was detected. The data are expressed as the means 6 SEM (n=3–4).
+P,0.05,
+++P,0.001 versus normal
control; *P,0.05, **P,0.01, ***P,0.001 versus STZ control. Graphic presentation of renal mRNA levels by real-time PCR analysis of rNALP3 (E), rASC
(F) and rCaspase-1 (G) at 7 weeks after STZ injection in different groups of rats as indicated. The relative mRNA levels were determined after
normalization with rGAPDH. The data are expressed as the means 6 SEM (n=3–4).
+++P,0.001 versus normal control; *P,0.05, **P,0.01, ***P,0.001
versus STZ control. Representative Western blot results (H) and graphic presentation showed renal maturation ratio of IL-1b (I) and IL-18 (J) in different
groups of rats as indicated. The data are expressed as the means 6 SEM (n=3–4).
+P,0.05,
++P,0.01 versus normal control; *P,0.05, **P,0.01 versus
STZ control.
doi:10.1371/journal.pone.0038285.g010
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with down-regulation of renal rOCTN2, an important transporter
for L-carnitine reabsorption, and reduction of renal and serum L-
carnitine levels, showing carnitine deficit in rats compared with
normal control group. High glucose increases levels of malonyl-
CoA, a CPT1 inhibitor and diminishes fatty acid b-oxidation
through ACC activation [51]. Consistent with the previous studies
in STZ-induced diabetic rats [52] and patients with type 2
diabetes [3], the present study demonstrated the decreased
expression levels of rCPT1 and p-rACC2 (Ser 219/Ser 221),
and the increased expression levels of rACC2 in the kidney of
STZ-induced diabetic rats compared with normal control group.
These results indicate that dysexpression of these renal lipid
metabolism-related genes, as well as carnitine deficiency may be
involved in fatty acid b-oxidation reduction, triggering hypertri-
glyceridemia to cause renal lipid accumulation injury in STZ-
treated rats. It is known that 12 h of fasting alters apolipoprotein
B-containing lipoproteins levels and induces TG but not choles-
terol accumulation in mice [37].Therefore, STZ-induced kidney
lipid metabolism disorder and lipid accumulation in rats super-
imposed on renal injury incurred with 12 h fasting in this study.
The activation of PPAR-a attenuates or inhibits lipotoxicity and
inflammation in diabetic microvascular disease [47]. Quercetin
and allopurinol improve dyslipidemia in fructose-fed rats [20,21],
the former reduces hepatic fat accumulation in Western-style diet-
fed mice [53]. Interestingly, quercetin and allopurinol ameliorated
abnormality of renal rPPAR-a, rCPT1, rOCTN2, rACC2 and p-
rACC2 expressions and L-carnitine levels, subsequently resulting
in the attenuation of renal lipid profile change and lipid
accumulation in this model. These results may suggest a possible
role of urate-lowering agents quercetin and allopurinol to suppress
the superimposed renal lipid metabolism disorder that occurs in
STZ-treated rats in this study.
The NLRP3 inflammasome is a multiprotein complex to
control caspase-1 activation step that is a prerequisite for the
maturation of IL-1b and IL-18. Recent studies document the role
of the NLRP3 inflammasome-caspase-1-IL-1b/IL-18 axis in
kidney disease [13,14,15]. In the diabetic state, elevation of
circulating and locally produced proinflammatory cytokines leads
to the persistence of inflammation, which correlates the develop-
ment and progression of diabetic kidney injury [2,8,9]. Thus,
inflammation is considered as a cardinal pathogenetic mechanism
in diabetic kidney injury [54]. Uric acid and lipid danger signals
are proposed to be important in activating the NALP3 inflamma-
some [7,11,12]. Consistent with renal inflammatory symptom
observed in STZ-induced diabetic rats with hyperuricemia and
renal lipid accumulation, the present study for the first time
demonstrated renal NLRP3 inflammasome activation evidenced
by over-expression levels of renal rNLRP3, rASC and rCaspase-1,
especially significantly increased levels of active form of Caspase-
1(P20), resulting in the maturation of IL-1b and IL-18 in STZ-
induced diabetic rats compared with normal control group. The
NLRP3 inflammasome activation and subsequent maturation and
secretion of IL-1b and IL-18 initiated further pro-inflammatory
events, producing kidney damage of STZ-induced diabetic rats.
Inflammation is demonstrated to be associated with lipid
metabolism in diabetic subjects [55]. IL-1b and IL-18 are reported
to affect metabolism of lipid and glucose [56,57]. Therefore, STZ-
induced NLRP3 inflammasome activation may further deteriorate
kidney lipid metabolism in rats. This finding of renal NLRP3
inflammasome activation may provide a mechanism underlying
renal inflammation and lipid accumulation after STZ induction
diabetes and may be a significant contributory factor for diabetic
kidney injury. Of note, additional studies have indicated that not
only NLRP3, but also NLRP1 [58], NLRC4 [NLR (Nod-like
receptor) family CARD-containing 4] [59] and AIM2 (absent in
melanoma 2) [60,61] form the inflammasomes that drive
inflammation in response to a wide variety of molecular patterns.
Similar to NLRP3, NLRP1 and AIM2 indirectly recruit and
thereby activate Caspase-1 through ASC. NLRC4 regulates
Caspase-1 activation and IL-1b processing in response to infection
with various gram-negative bacteria. Stimulation with STZ may
induce renal NLRP1, NLRC4 and AIM2 inflammasomes
assembly and Caspase-1 activation in rats. Dysregulation of these
inflammasomes may contribute to renal inflammation and lipid
metabolism in STZ-treated rats. Further studies for the detection
of the activation of renal NLRP1, NLRC4 and AIM2 inflamma-
somes in diabetic state are warranted.
Quercetin is capable of preventing high glucose-induced IL-1b
expression [62] and STZ-induced diabetic kidney injury in rats
[27]. Allopurinol successfully treats perforating collagenosis of
diabetes and renal failure [23]. Recently, allopurinol is found to
inhibit the NLRP3 inflammasome activation [7,19] and control
IL-1b production in inflammasome-deficient mice [7]. In this
study, the increased ratio of kidney weight to body weight and
renal inflammation in STZ-treated rats were significantly restored
by the treatment of quercetin and allopurinol. Quercetin and
allopurinol were firstly confirmed to suppress renal NLRP3
inflammasome activation characterized by down-regulation of
the NLRP3 and therefore reduction of Caspase 1 in STZ-treated
rats. Subsequently, Caspase-1 inhibition by quercetin and
allopurinol prevented kidney IL-1b and IL-18 release and over-
production triggered by hyperuricemia and dyslipidemia in this
model. These results of quercetin and allopurinol-produced
suppression of renal NLRP3 inflammasome activation were
parallel with their reductions of renal lipid accumulation in
STZ-treated rats. These findings suggest that urate-lowering
efficacy of quercetin and allopurinol may contribute to the
suppression of the NLRP3 inflammasome activation involved in
the normalization of IL-1b and IL-18 levels and reduction of renal
lipid accumulation, which may benefit to ameliorate kidney injury
of STZ-treated rats.
It is known that STZ is acutely nephrotoxic, leading to DNA
damage and cellular proliferation in rats up to 3 weeks after
60 mg/kg STZ iv administration [63], indicating that studies
examining the effects of drug treatments on the development of
diabetic nephropathy should not be started until at least 3 weeks
after STZ when the kidney has recovered from the acute mild
nephrotoxic effects of STZ [63–64]. On the other hand, the
NLRP3 inflammasome activation is involved in renal acute
tubular necrosis [14,40]. Moreover, in vivo ischemia/reperfusion
acutely increases renal cortical cholesterol ester, but not free
cholesterol levels in the kidney of mice [65]. Renal injury also
induces dramatic TG accumulation in proximal tubules/renal
cortex of CD-1 mice [66]. These observations indicate that renal
toxic injury and acute tubular necrosis are more likely related to
acute kidney lipid overload [65–66]. Moreover, 12 h of fasting
induces lipid accumulation and alters genes involved in lipid
metabolism in the kidney of mice [37]. In this study, it is
incompletely understood how renal acute injury, lipid accumula-
tion and inflammation interact and whether the combined effects
on STZ-induced nephrotoxicity in rats are additive or synergistic.
But, renal acute injury, lipid accumulation and inflammation
appear as a dangerous mix, and there may be important
superimposed effects of either condition with regard to crucial
triggers of nephrotoxicity in this model. In the present study, the
treatment of quercetin and allopurinol was started on the 4th day
after STZ injection in rats. So it is quite possible that the
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nephrotoxicity in STZ-diabetic rats should be attributed to
additive or synergistic effects rather than the treatment per se.
In conclusion, the present study demonstrated that STZ
induced renal expression abnormality of urate transport-related
proteins and lipid metabolism-related genes, showing hyperurice-
mia and dyslipidemia in diabetic nephropathy rats. Furthermore,
renal NLRP3 inflammasome activation was observed in STZ-
treated rats, resulting in elevation of IL-1b and IL-18, with
subsequent deterioration of renal injury. These findings may
provide evidence for the possible association between renal
NLRP3 inflammasome activation and lipid metabolism disorder
to superimpose causes of STZ-induced nephrotoxicity with
hyperuricemia in rats. The treatment of quercetin and allopurinol
with anti-hyperuricemic and anti-dyslipidemic effects may prevent
the superimposed nephrotoxicity induced by STZ in rats.
Although the detailed mechanisms of the nephroprotective effects
of quercetin and allopurinol on diabetic nephrotoxicity remain to
be fully defined, the present study should draw further attention to
the utility of urate-lowering agents such as quercetin and
allopurinol to gain new insights into the prevention of kidney
injury.
Acknowledgments
We thank Xing Wang for kind assistance in the animal studies.
Author Contributions
Conceived and designed the experiments: LDK. Performed the experi-
ments: CW YP QYZ FMW. Analyzed the data: CW YP. Wrote the paper:
LDK YP CW.
References
1. Ayodele OE, Alebiosu CO, Salako BL (2004) Diabetic nephropathy–a review of
the natural history, burden, risk factors and treatment. J Natl Med Assoc 96:
1445–1454.
2. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease.
Nat Rev Immunol 11: 98–107.
3. Murea M, Freedman BI, Parks JS, Antinozzi PA, Elbein SC, et al. (2010)
Lipotoxicity in diabetic nephropathy: the potential role of fatty acid oxidation.
Clin J Am Soc Nephrol 5: 2373–2379.
4. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin
Invest 115: 1111–1119.
5. Hovind P, Rossing P, Johnson RJ, Parving HH (2011) Serum uric acid as a new
player in the development of diabetic nephropathy. J Ren Nutr 21: 124–127.
6. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH (2009) Serum uric
acid as a predictor for development of diabetic nephropathy in type 1 diabetes:
an inception cohort study. Diabetes 58: 1668–1671.
7. Gasse P, Riteau N, Charron S, Girre S, Fick L, et al. (2009) Uric acid is a danger
signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.
Am J Respir Crit Care Med 179: 903–913.
8. Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory
cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433–442.
9. Dinarello CA, Donath MY, Mandrup-Poulsen T (2010) Role of IL-1beta in type
2 diabetes. Curr Opin Endocrinol Diabetes Obes 17: 314–321.
10. Moriwaki YT, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, et al. (2003)
Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of
patients with type 2 diabetes mellitus: relationship with diabetic nephropathy.
Metabolism 52: 605–608.
11. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, et al. (2010) NLRP3
inflammasomes are required for atherogenesis and activated by cholesterol
crystals. Nature 464: 1357–1361.
12. Rajama ¨ki K, Lappalainen J, Oo ¨rni K, Valimaki E, Matikainen S, et al. (2010)
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages:
a novel link between cholesterol metabolism and inflammation. PLoS ONE 5:
e11765.
13. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, et al. (2010) The NALP3
inflammasome promotes renal inflammation and contributes to CKD. J Am Soc
Nephrol 21: 1732–1744.
14. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, et al. (2010) An
inflammasome-independent role for epithelial-expressed Nlrp3 in renal
ischemia-reperfusion injury. J Immunol 185: 6277–6285.
15. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, et al. (2010)
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a
mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11:
897–904.
16. Estevez EC, Priego MP, Barbudo JA, Guijo PS (1990) Hyperuricemia-
hyperlipemia association in the absence of obesity and alcohol abuse. Clin
Rheumatol 9: 28–31.
17. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RKS, et al. (2010)
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1b
production via the ASC/caspase 1 pathway in monosodium urate monohydrate
crystal-induced gouty arthritis. Arthritis Rheum 62: 3237–3248.
18. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, et al. (2011)
The NALP3 inflammasome instigates obesity-induced inflammation and insulin
resistance. Nat Med 17: 179–188.
19. Griffith JW, Sun T, McIntosh MT, Bucala R (2009) Pure Hemozoin is
inflammatory in vivo and activates the NALP3 inflammasome via release of uric
acid. J Immunol 183: 5208–5220.
20. Hu QH, Wang C, Li JM, Zhang DM, Kong LD (2009) Allopurinol, rutin, and
quercetin attenuate hyperuricemia and renal dysfunction in rats induced by
fructose intake: renal organic ion transporter involvement. Am J Physiol Renal
Physiol 297: F1080–F1091.
21. Reungjui S, Roncal CA, Mu W, Srinivas TR, Sirivongs D, et al. (2007) Thiazide
diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol
18: 2724–2731.
22. Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, et al. (2009) Effect of
lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Am J Physiol Renal Physiol 297: F481–488.
23. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S (2010) Effect of
allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney
Dis 4: 128–132.
24. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M (2008) Quercetin
ameliorates metabolic syndrome and improves the inflammatory status in obese
Zucker rats. Obesity (Silver Spring) 16: 2081–2087.
25. Park J, Ahn J, Kim S, Ha TY (2008) Quercetin suppresses the hyperlipidemia
induced by an atherogenic diet in mice. FASEB J 22: lb707.
26. Chuang CC, Martinez K, Xie G, Kennedy A, Bumrungpert A, et al. (2010)
Quercetin is equally or more effective than resveratrol in attenuating tumor
necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary
human adipocytes. Am J Clin Nutr 92: 1511–1521.
27. Anjaneyulu M, Chopra K (2004) Quercetin, an anti-oxidant bioflavonoid,
attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 31:
244–248.
28. Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, et al. (2005) Erythromycin
ameliorates renal injury via anti-inflammatory effects in experimental diabetic
rats. Diabetologia 48: 2402–2411.
29. Abdel-Raheem IT, Abdel-Ghany AA, Mohamed GA (2009) Protective effect of
quercetin against gentamicin-induced nephrotoxicity in rats. Biol Pharm Bull 32:
61–67.
30. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, et al. (2007)
Quercetin reduces blood pressure in hypertensive subjects. J Nutr 137:
2405–2411.
31. Mahesh T, Menon VP (2004) Quercetin allievates oxidative stress in
streptozotocin-induced diabetic rats. Phytother Res 18: 123–127.
32. Minami M, Ishiyama A, Takagi M, Omata M, Atarashi K (2005) Effects of
allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterol-
emia-induced hypertensive rats. Blood Press 14: 120–125.
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
34. Hediger MA, Johnson RJ, Miyazaki H, Endou H (2005) Molecular physiology of
urate transport. Physiology (Bethesda) 20: 125–133.
35. Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors
(PPARs): novel therapeutic targets in renal disease. Kidney Int 60: 14–30.
36. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, et al. (2000) Molecular and
functional characterization of organic cation/carnitine transporter family in
mice. J Biol Chem 275: 40064–40072.
37. Krzystanek M, Pedersen TX, Bartels ED, Kjaehr J, Straarup EM, et al. (2010)
Expression of apolipoprotein B in the kidney attenuates renal lipid accumula-
tion. J Biol Chem 285: 10583–10590.
38. Kerner J, Hoppel C (2000) Fatty acid import into mitochondria. Biochim
Biophys Acta 1486: 1–17.
39. Wakil SJ, Abu-Elheiga LA (2008) Fatty acid metabolism: target for metabolic
syndrome. J Lipid Res 50 (Suppl). pp S138–S143.
40. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, et al. (2009) Necrotic
cells trigger a sterile inflammatory response through the Nlrp3 inflammasome.
Proc Natl Acad Sci USA 106: 20388–20393.
41. Keembiyehetty C, Augustin R, Carayannopoulos MO, Steer S, Manolescu A,
et al (2006) Mouse glucose transporter 9 splice variants are expressed in adult
liver and kidney and are up-regulated in diabetes. Mol Endocrinol 20: 686–697.
Quercetin Diminishes STZ-Diabetic Kidney Injury
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e3828542. Cheng QQ, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, et al.
(2008) Drug-metabolizing enzyme and transporter expression in a mouse model
of diabetes and obesity. Mol Pharm 5: 77–91.
43. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, et al. (2005) Regulation of
renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db/
db mice with type 2 diabetes. Diabetes 54: 2328–2335.
44. Hostetler HA, Huang H, Kier AB, Schroeder F (2008) Glucose directly links to
lipid metabolism through high affinity interaction with peroxisome proliferator-
activated receptor alpha. J Biol Chem 283: 2246–2254.
45. Frigerio F, Brun T, Bartley C, Madsen L, Poulain P, et al. (2010) Peroxisome
proliferator-activated receptor alpha (PPAR alpha) protects against oleate-
induced INS-1E beta cell dysfunction by preserving carbohydrate metabolism.
Diabetologia 53(2): 331–340.
46. Park CW, Kim HW, Ko SH, Usardi A, Bosco D, et al. (2006) Accelerated
diabetic nephropathy in mice lacking the peroxisome proliferator-activated
receptor alpha. Diabetes 55: 885–893.
47. Hiukka A, Maranghi M, Matikainen N, Taskinen MR (2010) PPAR alpha: an
emerging therapeutic target in diabetic microvascular damage. Nat Rev
Endocrinol 6: 454–463.
48. Eskandari HG, Cimen MY, Tamer L, Kanik A, Atik U (2004) Short term effects
of L-carnitine on serum lipids in STZ-induced diabetic rats. Diabetes Res Clin
Pract 66: 129–132.
49. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, et al. (2007)
Carnitine revisited: potential use as adjunctive treatment in diabetes.
Diabetologia 50: 824–832.
50. Ergun O, Ulman C, Kilicalp AS, Ulman I (2001) Carnitine as a preventive agent
in experimental renal ischemia-reperfusion injury. Urol Res 29: 186–189.
51. Farfari S, Schulz V, Corkey B, Prentki M (2000) Glucose-regulated anaplerosis
and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/
citrate shuttle in insulin secretion. Diabetes 49: 718–726.
52. Sun L, Halaihel N, Zhang W, Rogers T, Levi M (2002) Role of sterol regulatory
element-binding protein 1 in regulation of renal lipid metabolism and
glomerulosclerosis in diabetes mellitus. J Biol Chem 277: 18919–18927.
53. Kobori M, Masumoto S, Akimoto Y, Oike H (2011) Chronic dietary intake of
quercetin alleviates hepatic fat accumulation associated with consumption of a
Western-style diet in C57/BL6J mice. Mol Nutr Food Res 55: 530–540.
54. Navarro-Gonza ´lez JF, Mora-Ferna ´ndez C, de Fuentes MM, Garcı ´a-Pe ´rez J
(2011) Inflammatory molecules and pathways in the pathogenesis of diabetic
nephropathy. Nature Reviews Nephrology 7: 327–340.
55. Poulain-Godefroy O, Lecoeur C, Pattou F, Fru ¨hbeck G, Froguel P (2008)
Inflammation is associated with a decrease of lipogenic factors in omental fat in
women. Am J Physiol Regul Integr Comp Physiol 295: R1–7.
56. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, et al.
(2011) Inflammasome is a central player in the induction of obesity and insulin
resistance. Proc Natl Acad Sci USA 108: 15324–15329.
57. Olusi SO, Al-Awadhi A, Abraham M (2003) Relations of serum interleukin 18
levels to serum lipid and glucose concentrations in an apparently healthy adult
population. Horm Res 60: 29–33.
58. Fink SL, Bergsbaken T, Cookson BT (2008) Anthrax lethal toxin and
Salmonella elicit the common cell death pathway of caspase-1-dependent
pyroptosis via distinct mechanisms. Proc Natl Acad Sci USA 105: 4312–4317.
59. Arlehamn CSL, Petrilli V, Gross O, Tschopp J, Evans TJ (2010) The role of
potassium in inflammasome activation by bacteria. J Biol Chem 285:
10508–10518.
60. Poeck H, Bscheider M, Gross O, Finger K, Roth S, et al. (2010) Recognition of
RNA virus by RIG-I results in activation of CARD9 and inflammasome
signaling for interleukin 1 beta production. Nat Immunol 11: 63–69.
61. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES (2009) AIM2
activates the inflammasome and cell death in response to cytoplasmic DNA.
Nature 458: 509–513.
62. Wu CH, Wu CF, Huang HW, Jao YC, Yen GC (2009) Naturally occurring
flavonoids attenuate high glucose-induced expression of proinflammatory
cytokines in human monocytic THP-1 cells. Mol Nutr Food Res 53: 984–995.
63. Kraynak AR, Storer RD, Jensen RD, Kloss MW, Soper KA, et al. (1995) Extent
and persistence of streptozotocin-induced DNA damage and cell proliferation in
rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays.
Toxicol Appl Pharmacol 135: 279–286.
64. Tesch GH, Allen TJ (2007) Rodent models of streptozotocin-induced diabetic
nephropathy. Nephrology 12: 261–266.
65. Zager RA, Johnson A, Anderson K, Wright S (2001) Cholesterol ester
accumulation: an immediate consequence of acute in vivo ischemic renal
injury. Kidney Int 59: 1750–1761.
66. Zager RA, Johnson AC, Hanson SY (2005) Renal tubular triglyercide
accumulation following endotoxic, toxic, and ischemic injury. Kidney Int 67:
111–121.
Quercetin Diminishes STZ-Diabetic Kidney Injury
PLoS ONE | www.plosone.org 14 June 2012 | Volume 7 | Issue 6 | e38285